Contemporary Algorithm for the Management of Hepatocellular Carcinoma in 2021: The Northwestern Approach

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a major cause of cancer-related morbidity and mortality around the world. Frequently, concurrent liver dysfunction and variations in tumor burden make it difficult to design effective and standardized treatment pathways. Contemporary treatment guidelines designed for an era of personalized medicine should consider these features in a more clinically meaningful way to improve outcomes for patients across the HCC spectrum. Given the heterogeneity of HCC, we propose a detailed clinical algorithm for selecting optimal treatment using an evidence-based and practical approach, incorporating liver function, tumor burden, the extent of disease, and ultimate treatment intent, with the goal of individualizing clinical decision making.

Keywords

radioembolization - yttrium-90 - downstaging - transplantation - survival - interventional radiology

Publikationsverlauf

Artikel online veröffentlicht:
07. Oktober 2021

• References

• 1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
• 2 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013; 47 (Suppl): S2-S6
• 3 Salem R, Thurston KG. Radioembolization with ⁹⁰yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006; 17 (08) 1251-1278
• 4 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005; 7 (01) 35-41
• 5 Matsumoto MM, Mouli S, Saxena P. et al. Comparing real world, personalized, multidisciplinary tumor board recommendations with BCLC algorithm: 321-patient analysis. Cardiovasc Intervent Radiol 2021; 44 (07) 1070-1080
• 6 Salem R, Johnson GE, Kim E. et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable hepatocellular carcinoma: the LEGACY study. Hepatology 2021; (online ahead of print)
• 7 Salem R, Gabr A, Riaz A. et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology 2018; 68 (04) 1429-1440
• 8 Sohn JH, Duran R, Zhao Y. et al. Validation of the Hong Kong Liver Cancer Staging System in determining prognosis of the North American patients following intra-arterial therapy. Clin Gastroenterol Hepatol 2017; 15 (05) 746-755.e4
• 9 Salem R, Gilbertsen M, Butt Z. et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11 (10) 1358-1365.e1
• 10 Gabr A, Kallini JR, Gates VL. et al. Same-day ⁹⁰Y radioembolization: implementing a new treatment paradigm. Eur J Nucl Med Mol Imaging 2016; 43 (13) 2353-2359
• 11 Salem R, Gordon AC, Mouli S. et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016; 151 (06) 1155-1163.e2
• 12 Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150 (04) 835-853
• 13 Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis 2014; 34 (04) 444-455
• 14 Lewandowski RJ, Gabr A, Abouchaleh N. et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology 2018; 287 (03) 1050-1058
• 15 Riaz A, Gates VL, Atassi B. et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys 2011; 79 (01) 163-171
• 16 Vouche M, Habib A, Ward TJ. et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014; 60 (01) 192-201
• 17 Garin E, Tselikas L, Guiu B. et al; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6 (01) 17-29
• 18 Gabr A, Ranganathan S, Mouli SK. et al. Streamlining radioembolization in UNOS T1/T2 hepatocellular carcinoma by eliminating lung shunt estimation. J Hepatol 2020; 72 (06) 1151-1158
• 19 Liu PH, Hsu CY, Hsia CY. et al. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. Eur J Cancer 2016; 63: 25-33
• 20 Vitale A, Farinati F, Finotti M. et al; Associazione Italiana Per Lo Studio Del Fegato AISF HCC Special Interest Group, Italian Liver Cancer ITA LI CA Study Group. Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications. Cancers (Basel) 2021; 13 (07) 1673
• 21 Adcock CS, Puneky LV, Campbell GS. Favorable response of metastatic hepatocellular carcinoma to treatment with trans-arterial radioembolization followed by sorafenib and nivolumab. Cureus 2019; 11 (02) e4083
• 22 Wehrenberg-Klee E, Goyal L, Dugan M, Zhu AX, Ganguli S. Y-90 radioembolization combined with a PD-1 inhibitor for advanced hepatocellular carcinoma. Cardiovasc Intervent Radiol 2018; 41 (11) 1799-1802
• 23 Mao K, Yan Y, Zhang J. et al. The impact of liver resection on survival outcomes of hepatocellular carcinoma patients with extrahepatic metastases: a propensity score matching study. Cancer Med 2018; 7 (09) 4475-4484
• 24 Hsu CY, Liu PH, Hsia CY. et al. A new treatment-integrated prognostic nomogram of the Barcelona Clinic Liver Cancer System for hepatocellular carcinoma. Sci Rep 2017; 7 (01) 7914
• 25 Llovet JM, Ricci S, Mazzaferro V. et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (04) 378-390
• 26 Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: current and future. World J Gastroenterol 2019; 25 (24) 2977-2989
• 27 Lee MS, Ryoo BY, Hsu CH. et al; GO30140 Investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1B study. Lancet Oncol 2020; 21 (06) 808-820
• 28 Nishikawa H, Kita R, Kimura T. et al. Clinical implication of performance status in patients with hepatocellular carcinoma complicating with cirrhosis. J Cancer 2015; 6 (04) 394-402
• 29 Forner A, Gilabert M, Bruix J, Raoul JL. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol 2014; 11 (09) 525-535
• 30 Memon K, Kulik L, Lewandowski RJ. et al. Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression. J Hepatol 2013; 58 (01) 73-80
• 31 Kim YS, Lim HK, Rhim H. et al. Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 2013; 58 (01) 89-97
• 32 European Association for Study of Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer 2012; 48 (05) 599-641
• 33 Crocetti L, de Baere T, Lencioni R. Quality improvement guidelines for radiofrequency ablation of liver tumours. Cardiovasc Intervent Radiol 2010; 33 (01) 11-17
• 34 Gabr A, Kulik L, Mouli S. et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology 2021; 73 (03) 998-1010
• 35 Nagai S, Kitajima T, Yeddula S. et al. Effect of mandatory 6-month waiting period on waitlist and transplant outcomes in patients with hepatocellular carcinoma. Hepatology 2020; 72 (06) 2051-2062
• 36 Gabr A, Riaz A, Mouli S. et al. Modified radiation lobectomy: an evolving paradigm to convert patients to liver resection candidacy. Semin Intervent Radiol 2019; 36 (04) 343-348
• 37 Gabr A, Polineni P, Mouli SK, Riaz A, Lewandowski RJ, Salem R. Neoadjuvant radiation lobectomy as an alternative to portal vein embolization in hepatocellular carcinoma. Semin Nucl Med 2019; 49 (03) 197-203
• 38 Gabr A, Abouchaleh N, Ali R. et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2018; 29 (11) 1502-1510.e1
• 39 Lewandowski RJ, Kulik LM, Riaz A. et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9 (08) 1920-1928
• 40 Chow PK, Gandhi M, Gebski V. The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma. Future Oncol 2017; 13 (25) 2213-2216
• 41 Sato K, Lewandowski RJ, Bui JT. et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc Intervent Radiol 2006; 29 (04) 522-529
• 42 Abouchaleh N, Gabr A, Ali R. et al. ⁹⁰Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med 2018; 59 (07) 1042-1048
• 43 Salem R, Lewandowski R, Roberts C. et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15 (04) 335-345
• 44 Gordon AC, Gabr A, Riaz A. et al. Radioembolization super survivors: extended survival in non-operative hepatocellular carcinoma. Cardiovasc Intervent Radiol 2018; 41 (10) 1557-1565
• 45 Tella SH, Mahipal A, Kommalapati A, Jin Z. Evaluating the safety and efficacy of nivolumab in patients with advanced hepatocellular carcinoma: evidence to date. OncoTargets Ther 2019; 12: 10335-10342
• 46 Zhu AX, Finn RS, Edeline J. et al; KEYNOTE-224 Investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19 (07) 940-952
• 47 Kulik LM, Atassi B, van Holsbeeck L. et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94 (07) 572-586